Novartis MS Pill Gilenya Patient Gets Rare Brain Disease

UPDATE: Novartis MS Pill Gilenya Patient Gets Rare Brain Disease - WSJ.com 
 April 13, 2012, 6:22 a.m. ET

UPDATE: Novartis MS Pill Gilenya Patient Gets Rare Brain Disease

-- Development comes as Gilenya's safety is under scrutiny by European regulators
-- Patient had been previously treated with Elan and Biogen's MS drug Tysabri
-- Analysts say case should be taken seriously as adds to Gilenya safety concerns
(Adds detail throughout on patient's case, analyst comment, background, and updates share price)

By Marta Falconi
Of DOW JONES NEWSWIRES
ZURICH (Dow Jones)--Novartis AG (NVS) Friday said a patient treated with its multiple-sclerosis pill Gilenya has been diagnosed with a rare and often fatal brain disease.
The Swiss drug maker said the patient, whose identity has not been disclosed, had been ...

• Journal Community